cliccando qui - Aristea

17
FAMPRIDINE IS EFFECTIVE ON WALKING ABILITY IN A SUBGROUP OF
MULTIPLE SCLEROSIS PATIENTS
C. Solaro1, E. Trabucco1 , M. Cella1, P. Tanganelli1
1 Dept Head and Neck Neurology ASL3 Genovese, Genova
BACKGROUND: Multiple sclerosis (MS) is one of the most common neurological
diseases and involves inflammatory demyelination and axonal loss of the central
nervous system. Physiologically, myelin loss leads to changes in axonal ion channels
that cause conduction failure. Fampridine (4-aminopyridine) is a potassium channel
blocker that can increase action potential duration and amplitude, leading to improved
conduction in demyelinated nerve fibers and to increased neurotransmitter release at
synaptic endings.
OBJECTIVE: The aim of the study is to assess the efficacy on walking ability of
fampridine in patients with MS.
MATERIALS AND METHODS: 16 patients were assigned to receive fampridine (10 mg
twice daily) for 2 weeks. A battery of tests including Symbol Digit (SD), Nine Hole Peg
Test (9HPT), Fatigue Severity Scale (FSS), 12-item Multiple Sclerosis Walking Scale
(MSWS-12), Two Minutes Walking Test (2MWT) and Timed 25-foot Walk (T25FW)
was performed at baseline (T0), at the end of treatment (T1) and 2 weeks later (T2).
Responders had been defined by the literature as subjects with an improvement at the
T25FW greater than 20%
RESULTS: Out of 16 subjects were 8 female and 8 male. Mean age was years 52,4 ,
mean disease duration 14 years, 7 (46,6 %) subjects had relapsing remitting, 4 (26,7
%) secondary progressive and 4 (28,7 %) had primary progressive disease course.
Mean EDSS score was 5,6. A significant improvement (>20%) in walking speed was
observed in 4 patients, 3 patients were “partial responders” with a subjective
improvement in walk and 8 patients were “no responders”. 1 patient dropped out from
the study due to side effects (doffuse paresthesia and facial mioclonus). Results at the
others scale will be presented.
CONCLUSION: Fampridine improved walking ability in a subgroup of people with
multiple sclerosis. This improvement was associated with a reduction of disability and
an increase in quality of life as reported by patients.
Bari, 18-20 Aprile 2013
FAMPRIDINE IS EFFECTIVE ON WALKING ABILITY IN A SUBGROUP OF
MULTIPLE SCLEROSIS PATIENTS
C. Solaro1, E. Trabucco1 , M. Cella1, P. Tanganelli1
1 Dept Head and Neck Neurology ASL3 Genovese, Genova
BACKGROUND: Multiple sclerosis (MS) is one of the most common neurological
diseases and involves inflammatory demyelination and axonal loss of the central
nervous system. Physiologically, myelin loss leads to changes in axonal ion channels
that cause conduction failure. Fampridine (4-aminopyridine) is a potassium channel
blocker that can increase action potential duration and amplitude, leading to improved
conduction in demyelinated nerve fibers and to increased neurotransmitter release at
synaptic endings.
OBJECTIVE: The aim of the study is to assess the efficacy on walking ability of
fampridine in patients with MS.
MATERIALS AND METHODS: 16 patients were assigned to receive fampridine (10 mg
twice daily) for 2 weeks. A battery of tests including Symbol Digit (SD), Nine Hole Peg
Test (9HPT), Fatigue Severity Scale (FSS), 12-item Multiple Sclerosis Walking Scale
(MSWS-12), Two Minutes Walking Test (2MWT) and Timed 25-foot Walk (T25FW)
was performed at baseline (T0), at the end of treatment (T1) and 2 weeks later (T2).
Responders had been defined by the literature as subjects with an improvement at the
T25FW greater than 20%
RESULTS: Out of 16 subjects were 8 female and 8 male. Mean age was years 52,4 ,
mean disease duration 14 years, 7 (46,6 %) subjects had relapsing remitting, 4 (26,7
%) secondary progressive and 4 (28,7 %) had primary progressive disease course.
Mean EDSS score was 5,6. A significant improvement (>20%) in walking speed was
observed in 4 patients, 3 patients were “partial responders” with a subjective
improvement in walk and 8 patients were “no responders”. 1 patient dropped out from
the study due to side effects (doffuse paresthesia and facial mioclonus). Results at the
others scale will be presented.
CONCLUSION: Fampridine improved walking ability in a subgroup of people with
multiple sclerosis. This improvement was associated with a reduction of disability and
an increase in quality of life as reported by patients.